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Background
There is a strong association between hepatitis B virus 
(HBV), hepatitis C virus (HCV) and human immunodeﬁciency 
virus (HIV) infection (1, 2). All three infections are transmitted 
through intravenous drug abuse or sexual contact, although 
the latter route is not a usual way of HCV transmission (3-5). 
Hepatitis A, B and C are considered as “desmoteric” infections, 
which mean their prevalence is generally higher in prisoners 
than in non-prisoners. Many studies showed that imprisonment 
is an important predictor of HBV, HCV and HIV infection (6-10). 
Prison conditions increase the risk of transmission of infec-
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ABSTRACT
Background: There is a strong association between hepatitis B virus (HBV), hepatitis C virus (HCV) and 
human immunodeﬁciency virus (HIV) infection which are mainly transmitted by contamination 
with blood via intravenous drug abuse (IVDU) or sexual contact. 
Objectives: To determine the prevalence of these infections and the risk factors associated with them 
among prisoner and non-prisoner IVDUs in Tehran, Iran. 
Patients and Methods: This cross-sectional study was performed in two jails and three drug rehabilita-
tion centers between 2001 and 2002 in Tehran. HBsAg and HBcAb were checked using highly speciﬁc 
third generation enzyme immunoassays (DIA.PRO, Italy, speciﬁcity >99%, and Radim, Italy, speciﬁcity 
99.7%, respectively). HCVAb was detected using ELISA (DIA.PRO, Italy) with both sensitivity and speciﬁ-
city >98%. HIVAb test (DRG Diagnostics kit, Germany) was performed for 459 of the 468 IDU subjects.
Results: 392 prisoners and 135 individual attending drug rehabilitation centers were approached. Of 
the 518 subjects studied, 464 (89.5%) were male, 386 (74.5%) were prisoners and 132 (25.5%) were non-
prisoners. In this study, HBsAg, HCVAb and HIVAb were positive in 19 (3.7%), 359 (69.5%) and 70 (15.5%) 
of subjects, respectively. These tests were positive in 17 (4.5%), 311 (80.5%) and 63 (17%) among prisoners 
and 2 (1.5%), 48 (36.5%) and 7 (7.8%) in non-prisoners, respectively. Multiple logistic regression analysis 
revealed that independent factors related to co-infection of HCV and HIV infection were imprison-
ment (p<0.001. OR: 7.5) and using common syringe (p=0.03, OR: 4.5). 
Conclusions: Our ﬁndings strongly suggest that drug injection inside prison carries is a risk for HIV in-
fection and that HIV infection among IDUs is likely to be bridged to the broader population through 
sexual contact without using eﬀective prevention programs.
  Implication for Health policy/practice/research/medical education:
Past history of being in a prison is discussed as one of the risk factors of acquiring Hepatitis B infection especially among IV drug abusers. Family 
physicians, health policy makers, authorized person in the health system of prisons should read this important article. Besides, this should be more 
considered for NGO’s which are active for improvement of health conditions in the public places like prisons.
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tions, including blood-borne viral infections; the risk is further 
increased by the use of unsterile equipment used for injection 
(11). Intravenous drug users (IDUs) are at a potential risk for ac-
quiring blood-borne infections by parenteral and sexual routes. 
In many research, HBV, HCV and HIV infections have been found 
to coexist in IDUs (12-16). However, there is scant information 
on the risk factors associated with these co-infections and their 
prevalence in Iran.
Objectives
Given a large proportion of prisoners are drug addicts, we 
conducted this study to determine the prevalence of these infec-
tions and the risk factors associated with them among prisoner 
and non-prisoner IDUs in Tehran, Iran.20
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Patients and Methods
This cross-sectional study was performed in two jails and three 
drug rehabilitation centers. The authorities of these places in 
Tehran were informed about the possible high rates of HBV and 
HCV infections among IVDUs and the potential risks and com-
plications of HIV infection. In this study, an IVDU was deﬁned 
as “a person using any kind of injectable drug (i.e., heroin, co-
caine, opium, etc) regularly for at least one year.” Prison inmates 
were selected at random; IVDUs attending the three reference 
drug treatment centers in Tehran were enrolled consecutively. 
Researchers met groups of 20–40 prisoners each time when 
the purpose and the nature of the study was fully explained for 
them. They were informed of the consequences of HBV, HCV and 
HIV infections. They were reassured that the study information 
would remain conﬁdential and that participation in the study 
was voluntary. Prisoners were also approached individually, if 
so desired. After obtaining written informed consent from each 
subject, a questionnaire was completed to assess the probable 
risk factors for HBV, HCV and HIV infections. The questionnaire 
covered questions related to demography, socioeconomic sta-
tus, marital status, level of education, occupation, pattern and 
type of intravenous drug used, duration of drug injection, use 
of shared injecting equipment, sexual behavior, traditional 
blood letting (hejamat), dental procedures, surgical operation, 
history of blood transfusion, ear piercing, and tattooing. After 
completing the questionnaire, 5 mL of blood was drawn from 
each subject and transferred into a sterile disposable Falcon 
tube. A similar identiﬁer code was assigned to the questionnaire 
and blood sample. The blood samples were transported to the 
laboratory of the Digestive Disease Research Center in Shari-
ati Hospital, Tehran within 2–5 hours at 2–8 °C. They were then 
centrifuged and sera were separated and transferred to a sterile 
tube with the same code. The sera were then stored at  -70 °C 
until processing, which was done once the specimen collection 
was complete. HBsAg and HBcAb were checked using highly 
speciﬁc third generation enzyme immunoassays (DIA.PRO, Italy, 
speciﬁcity >99%, and Radim, Italy, speciﬁcity 99.7%, respectively). 
HCVAb was detected using ELISA (DIA.PRO, Italy) with both sensi-
tivity and speciﬁcity >98%. HIV testing (DRG Diagnostics kit, Ger-
many) was performed for 459 of the 468 IDU subjects. One HIV-
positive subject was excluded from the study due to incomplete 
data. The tests were performed by one laboratory technician.
Statistical analysis
SPSS® ver 15 for Windows® (SPSS Inc, Chicago, IL, USA) was 
used for all analyses. X2 and Fisher's exact tests were used to 
ﬁnd the correlation between imprisonment and probable risk 
factors. Student’s t-test and one-way ANOVA were used for com-
parison of means of continuous variables. Independent predic-
tors of disease transmission were identiﬁed by multiple logistic 
regression analysis, with backward stepwise variable selection. 
A p<0.05 was considered statistically signiﬁcant.
Results
In this study 392 prisoners and 135 individual attending drug 
rehabilitation centers were approached. Of them, ﬁve prisoners 
and three non-prisoners refused to participate. Personal prefer-
ence was the only reason to refuse participation in this study. 
One of the subjects was also check for HIV only and was therefore 
excluded from the study. Of the 518 subjects studied, 464 (89.5%) 
were men, 386 (74.5%) were prisoners and 132 (25.5%) were non-
prisoners. HBsAg, HBcAb and HCVAb were checked for all 518 
subjects; HIVAb was also tested in a subset of 458 subjects. Sixty 
subjects did not agree to test for HIV and were thus excluded for 
this test. In this study HBsAg, HCVAb and HIVAb were positive in 
19 (3.7%), 359 (69.5%) and 70 (15.5%) of subjects, respectively. These 
tests was positive in 17 (4.5%), 311 (80.5%) and 63 (17%) among pris-
oners and 2 (1.5%), 48 (36.5%) and 7 (7.8%) in non-prisoner, respec-
tively. The prevalence of Confection with HBsAg+ and HCVAb+, 
There are signiﬁcant diﬀerences (p<0.001)between prisoners and non-prisoners for all studied variables.
Viral  markers     Total  (%)    prisoner  (%)   Non-prisoner  (%)
HBsAg+  HCVAb+     16  (3.1)    16  (4.1)    0
HBsAg+  HIVAb+     3  (0.6)    3  (0.8)    0
HCVAb+  HIVAb+     58  (11.2)    56  (14.5)    2  (1.5)
HBSAg+  HCVAb+  HIVAb+    3  (0.6)    3  (0.8)    0
Table 1. Co-infection of viral markers in prisoners and non-prisoners 
a Independent samples Student’s t-test 
b x2 test
Table 2. Comparison of risk factors for disease transmission between prisoners and non-prisoners
Variables            Total    Prisoner      Non-prisoner      p-value
          No. (%)      No. (%)      No. (%)
Mean age (year)           35.24    35.85    33.45     0.007  a
Gender                              
           464  (89.6)   336  (72)    128  (28)     0.001  b
               54 (10.4)    50 (93)      4 (7)
Mean duration of            4.533    4.78    3.78     0.02  a
IVDU (year) 
History of sharing        321 (62)      255 (79 )      66 (21)        0.001 b
needle 
History of tattooing      272 (52.5)    230 (85)      42 (15)        <0.001 b
History of         272 (52.5)    182 (67)      90 (23)        <0.001 b
heterosexual 
History of        53 (10.21)    27 (51)      26 (49)        <0.001 b
homosexual 
Bisexual            49  (9.5)    23  (47)    26  (53)     <0.001  b
Male
Female Mir-Nasseri MM et al. 21
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HBsAg+ and HIVAb+, HCVAb+ and HIVAb+ and triple infection 
with HBV, HCV and HIV is presented in Table 1. The prevalence of 
co-infection was signiﬁcantly higher in prisoners in all the stud-
ied groups. In the next step, we sought to compare risk factors 
for disease transmission in these two groups. As presented in 
Table 2, all known risk factors related to infection transmission 
are signiﬁcantly higher in prisoners compared to non-prisoners 
(p<0.001 in all variables). Finally, multiple logistic regression 
analysis revealed that independent factors related to co-infec-
tion of HCV and HIV were “imprisonment” (p<0.001; OR: 7.5) 
and using common syringe (p=0.03; OR: 4.5).
Discussion
To better understand the risk of blood-borne infection in rela-
tion to imprisonment in IVDUs, we evaluated the prevalence of 
HBV, HCV and HIV and also co-infection among IVDUs in prisons 
and IVDUs who attended drug rehabilitation centers and com-
pared risk factors of disease transmission between these two 
groups. We found that blood-borne infection and co-infection 
of the studied diseases are signiﬁcantly more prevalent among 
IVDUs than general population of Iran which is mainly due to 
risky behaviors in the latter group. In this study, we were able 
to show that independent predictors of HCV and HIV co-infec-
tion are history of sharing needle and imprisonment and that 
each of which increases the risk of co-infection. This result in-
dicates that imprisonment increases the risk of co-infection by 
7.5-fold. This can be attributed to the higher risky behaviors dur-
ing the incarceration including using common needle, razors, 
and even practicing unsafe sexual behaviors. This hypothesis 
is conﬁrmed in several other studies. In a study by Zamani, et 
al, (17) on IVDU participants, infection was strongly associated 
with a history of shared drug injection inside prison, whereas it 
was not signiﬁcantly associated with shared drug injection out-
side prison. Similar ﬁndings have been reported from Thailand, 
where drug injecting inside prison was shown to associate with 
HIV infection among prisoners (18). The risk of disease transmis-
sion is also related to the length and number of incarceration 
as conﬁrmed in a study that length of incarcerations increased 
the risk of HCV infection by 3.5-fold (19). In another study among 
community based drug users in Tehran, the prevalence of HIV 
infection was 23.2% among male IVDUs. In a multivariate analy-
sis, a history of shared drug injection inside prison (OR: 2.5) 
and multiple incarcerations (OR: 3.13) were associated with a 
signiﬁcantly higher prevalence of HIV infection (20). Clinically, 
co-infection of HBV with HIV and HCV with HIV is also impor-
tant. The natural history of chronic hepatitis B and C is altered 
by simultaneous infection with HIV. Immune control of HBV is 
negatively aﬀected by HIV leading to reduction of HBsAg clear-
ance. Furthermore, HIV increases the HBV viral load (21). In un-
treated HIV population, faster progression to liver cirrhosis is 
reported for HBV/HIV patients (22). Furthermore, hepatocellular 
carcinoma may develop at a younger age and with a more ag-
gressive presentation (23). Co-infection of HCV with HIV is also 
a major public health problem. Of the 33.4 million HIV-infected 
individuals in the world in 2008, it is estimated that at least ﬁve 
million are co-infected with HCV. Recent data from the United 
State of America indicate that, 25%–30% of patients with HIV are 
co-infected with HCV (24) reﬂecting the contribution of at high 
risk population such as prison inmates. Also, 65%–70% of HIV-
positive prisoners in the US are co-infected with HCV compared 
to 18%–25% of HIV-positive in general population (25). In the 
natural course of HCV, it is evident that co-infection with HIV re-
duces the immune response to HCV and diminishes the chance 
of spontaneous clearance. Many studies revealed that the pres-
ence of HIV in HCV subjects leads to faster disease progression 
and liver failure (26). It is therefore clear that co-infection of 
these three blood-borne infections is a serious epidemiological 
and clinical problem worldwide as well as Iran. These diseases 
can easily transferred among high risk population, especially 
in prisons where many individual with diﬀerent diseases are 
kept in places with low hygiene. Therefore, harm reduction 
programs should urgently be expanded in prisons and in cor-
rectional centers to prevent transmission of these diseases to 
susceptible persons.Prevalence of infection with hepatitis B 
and C is high in those with high risk behaviors including IVDUs 
and persons with unsafe sex practice particularly among pris-
oners. This can be more complicated and increase the burden 
of diseases by co-infection with HIV. Therefore, it is imperative 
to implement some strategies like harm reduction program to 
reduce the burden of blood-borne infection among prisoners 
which directly inﬂuences the transmission of these diseases to 
the community.
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